Aveanna Healthcare Holdings (AVAH) has received a new Buy rating, initiated by William Blair analyst, Ryan Daniels.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ryan Daniels’s rating is based on Aveanna Healthcare Holdings’ ability to provide high-quality home care services, which are increasingly preferred by payers for their cost-effectiveness and patient satisfaction. The case study of Liam, a premature infant transitioning from NICU to home care, highlights Aveanna’s capability in delivering specialized care that results in better patient outcomes and experiences.
Furthermore, Daniels points out that Aveanna’s shares are trading at a valuation that aligns with industry peers, yet the company’s strong EBITDA growth prospects justify a premium. This growth potential, coupled with a predictable revenue stream from preferred payers, underpins the Buy rating for Aveanna’s stock.
According to TipRanks, Daniels is a 3-star analyst with an average return of 4.7% and a 44.63% success rate. Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Addus Homecare, and Idexx Laboratories.